Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-8000 plus nivolumab in metastatic melanoma
NCT04674683Phase 3Active, not recruiting
- Sponsor
- HUYABIO International, LLC
- Start
- Aug 2021
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of tucidinostat in melanoma, sponsored by HUYABIO International, LLC. Started Aug 2021; status: active, not recruiting.
02
Drugs
tucidinostat
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04674683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674683.